Loading patent…
AssigneeCentro De Inmunologia Molecular
InventorsRolando Rodriguez, Gisela Marinello, Tania Ramos, Irene Del Gado
Estimating the term…
The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.
An immunotherapy combination which inhibits the growth and/or proliferation of cells,:
The immunotherapy combination according to claim 39, wherein the antibody against the EGF is a monoclonal antibody.
An immunotherapy treatment combination which inhibits the growth and/or proliferation of cells, wherein the growth of said cells is dependent on interaction between a receptor with tyrosine kinase activity (RTK) and its ligand, comprising
An immunotherapy treatment combination which inhibits the growth and/or proliferation of cells, wherein the growth of said cells is dependent on interaction between a receptor with tyrosine kinase activity (RTK) and its ligand, comprising a) an antibody against a ligand of an RTK receptor, and b) a vaccine which induces antibodies against a ligand of an RTK receptor.
An immunotherapy treatment combination which inhibits the growth and/or proliferation of cells, wherein the growth of said cells is dependent on interaction between a receptor with tyrosine kinase activity (RTK) and its ligand, comprising a) an vaccine which induces antibodies against a ligand of an RTK receptor, and b) a vaccine which induces antibodies against a second ligand of the RTK receptor.
An immunotherapy combination for reducing the size of a tumor, wherein the growth of said tumor is dependent on interaction between a receptor with tyrosine kinase activity (RTK) and its ligand, comprising
Dependencies are inferred from the claim text.